Epitalon vs Orforglipron
Compare the research profiles of Epitalon and Orforglipron. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesEpitalon
Epitalon (Epithalon)
anti-aging
Preclinical
not-approved
Orforglipron
Orforglipron (LY3502970)
weight-loss
Phase 3 Clinical Trials
clinical-trials
Detailed Comparison
| Aspect | Epitalon | Orforglipron |
|---|---|---|
| Overview | A synthetic tetrapeptide studied for telomerase activation and potential anti-aging effects. Developed by Russian scientist Vladimir Khavinson. Popular in longevity circles.... | The most anticipated upcoming weight loss drug - the first oral non-peptide GLP-1 receptor agonist. Unlike current oral options, it does not require fasting before consumption, potentially removing a ... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Believed to activate telomerase, the enzyme that maintains telomere length. Telomere shortening is associated with aging, so maintaining length could ... | Small molecule that activates GLP-1 receptors orally without the peptide structure. Provides similar effects to injectable GLP-1s but in pill form.... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.